<DOC>
	<DOCNO>NCT02308540</DOCNO>
	<brief_summary>Phase 1/2 , Prospective , Single Center , Randomized , ActiveControlled , Double-Blind , Age De-escalation Study assess safety tolerability SIILPCV10 administer single-dose regimen healthy Gambian pneumococcal conjugate vaccine ( PCV ) -naïve young adult PCV-primed toddler 4 week post vaccination . Each adult toddler subject undergo total 4 clinic visit . Each infant subject undergo total 9 schedule visit . Blood collect subject screen visit safety potential immunological assessment , 28 day completion vaccination schedule immunological assessment . For adult , vaccine give IM mid-deltoid muscle nondominant arm use 24-gauge needle . For toddler infant , vaccine give IM anterolateral aspect leave thigh . Blood collect adult toddler safety labs Day 7 post-vaccination visit .</brief_summary>
	<brief_title>Safety Immunogenicity 10 Valent Pneumococcal Conjugate Vaccine ( SIILPCV10 ) Healthy Adults , Toddlers , Infants</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>• Healthy adult ( 1840 yr ) , toddler ( 1215 mo ) , full term infant ( 68 wks ) ≥ 3.5 kg Able provide inform consent ( child ) Willing comply study requirement procedure . Toddlers complete Gambian infant EPI schedule Infants receive birth dos BCG , HepB OPV receive additional vaccine . Infants toddler weighttoheight Z score ≥ 2 . Subjects resident study area plan travel outside study area period study participation . Use investigational medicinal product within 90 day prior randomization throughout study . Ingestion herbal traditional local medication within 14 day randomization . Adults infant previously vaccinate S. pneumoniae . History S. pneumoniae infection confirmed culture normally sterile site . History allergic disease history serious reaction prior vaccination know hypersensitivity component study vaccine . History anaphylactic shock . Screening laboratory test vital sign outside normal range . HIVpositive HbsAg positive base test screening . Acute illness ( moderate severe ) and/or fever ( axillary temperature ≥ 38.0°C adult ≥ 37.5°C toddler infant ) . Use antibiotic within 5 day randomization ( exclude treatment malaria ) . A positive test malaria time screening , remain positive post treatment retested time randomization ( Day 0 ) . Administration nonstudy vaccine within 30 day prior administration study vaccine plan vaccination course study participation . Chronic administration immunosuppressant immune modifying drug prior administration study . The use topical inhaled glucocorticoid permit . Administration immunoglobulins and/or blood product within 6 month prior administration study vaccine study period . History known disturbance coagulation blood disorder could cause anemia excess bleeding . Employee , direct descendant person employ Sponsor , CRO , PI , study site personnel , site . Adults Recent history sign alcohol substance abuse . History major psychiatric disorder . Female adult subject pregnant breastfeeding . Infants/Toddlers Family history suspect primary immunodeficiency firstdegree relative . Had sibling die suddenly without apparent cause precede illness first year life . Evidence clinically significant congenital abnormality judge PI . Evidence fetal alcohol syndrome maternal history alcohol abuse pregnancy . History meningitis , seizures neurological disorder . Evidence exposure HIVpositive individual maternal fetal transmission , breast milk , bloodborne mechanism</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>